September 3rd 2024
The TARGET-DERM registry longitudinal study highlighted the continued trend of the failure to escalate atopic dermatitis treatments when patients do not meet their therapeutic targets.
September 2nd 2024
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Cornerstone therapy in atopic dermatitis
January 22nd 2018Moisturizers were described as the “cornerstone of therapy” in atopic dermatitis in the 2014 AAD guidelines for topical therapies in atopic dermatitis, but the products differ greatly by ingredients which can improve the condition or make it worse.
Caffeine can reduce inflammation in patients with eczema and psoriasis
December 1st 2017Adding caffeine to topical skin treatments would be a simple way to reduce inflammation in patients with atopic dermatitis and psoriasis, suggests a review presented at the Psoriasis: From Gene to Clinic International Congress, which took place in London this week.
Atopic dermatitis phenotypes may indicate outcomes
October 3rd 2017Children under two years old with signs of atopic dermatitis have an increased risk of developing asthma and food allergies, researchers report in JAMA Pediatrics. And, young children with both early onset atopic dermatitis and a food allergy, have a “very high risk” of developing asthma or allergic rhinitis.
Dupilumab maintains long-term benefits in atopic dermatitis
July 11th 2017Long-term data for dupilumab in atopic dermatitis revealed at the American Academy of Dermatology (AAD) 75th Annual Meeting reflect safety, rapid relief of troublesome symptoms and a long-lived response in keeping with the drug’s breakthrough status, experts told Dermatology Times.